For the year ending 2025-12-31, SLNCF made $559K in revenue. -$88,612K in net income. Net profit margin of -15851.88%.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Revenue | 559 | |||
| Cost of sales | 215 | |||
| Gross profit | 344 | |||
| Research and development costs | 67,753 | |||
| General and administrative expenses | 22,344 | |||
| Restructuring charges | 1,324 | |||
| Operating loss | -91,077 | |||
| Foreign currency (loss)/gain, net | -8,467 | |||
| Other income, net | 3,480 | |||
| Benefit from r&d credit | 7,463 | |||
| Loss before income tax expense | -88,601 | |||
| Income tax expense | 11 | |||
| Net loss | -88,612 | |||
| Basic EPS | -0.63 | |||
| Diluted EPS | -0.63 | |||
| Basic Average Shares | 141,694,702 | |||
| Diluted Average Shares | 141,694,702 | |||
Silence Therapeutics plc (SLNCF)
Silence Therapeutics plc (SLNCF)